Free Republic

Metformin is a widely prescribed drug for managing type 2 diabetes. In recent years, indications of its potential anticancer properties have emerged in research. A study has found that metformin activates the body's immune cells. The effect was particularly observed in what are known as dendritic cells, which are the most effective in helping the immune system identify cancer cells as foreign entities. "Our study found that metformin contributed to the metabolism of dendritic cells so that they became active and enhanced the immune response against cancer cells," says Rita Turpin. Identifying this effect can help to develop anticancer therapies...

More than 150 students, staff and alumni have reportedly been diagnosed with cancers and other diseases linked to a university building teeming with toxins. Cases of lymphoma and thyroid and breast cancers have been reported among patients who spent time at Poe Hall, a class building at North Carolina State University in Raleigh. The building closed in November 2023 amid reports of exposure to concerning levels of polychlorinated biphenyls (PCBs), toxic chemicals linked to cancer. An investigation the month before found that PCB levels in five rooms were more than 38 times the Environmental Protection Agency's (EPA) building limit. The...

Yesterday the Expose published an article which highlighted just a few of the various diseases that were found to be potentially caused by parasites, including cancers. A recent review of nine published research papers by Doctor William Makis further supports the views in the article, but Dr Makis is more qualified to say “it is a reasonable hypothesis that COVID-19 mRNA Vaccine Turbo Cancer patients could benefit significantly from anti-parasitic drugs.” One anti parasitic drug in particular, Fenbendazole, however, has not been sanctioned for human use by the FDA, but despite lacking “official” approval, it is cheap, safe and more...

Research has found that hormone levels, measured through blood tests, are an important indicator of whether women will benefit from recently licensed medication for the prevention of breast cancer. Aromatase inhibitors such as anastrozole are recommended as an option for preventive therapy in post-menopausal women at high risk of breast cancer. Post-menopausal women who have higher concentrations of the hormone estrogen in their bloodstream are at higher risk of developing breast cancer. Aromatase inhibitors stop the production of estrogen and reduce the amount made in the body. They are currently the most effective preventive agent for estrogen-receptor positive breast cancer,...

Chemotherapy-induced peripheral neuropathy (CIPN)—nerve pain, tingling, or numbness in the hands or feet—is a common side effect of certain cancer treatments, including two drugs frequently used to treat cancer—the taxanes paclitaxel and docetaxel. Initial results from a large study that tracked CIPN in more than 1,100 patients treated for breast cancer with a taxane show a pattern of clinically meaningful, persistent sensory and motor symptoms, with patients experiencing more severe symptoms with paclitaxel than with docetaxel. Michael J. Fisch, MD, said "These results are highly relevant because taxanes such as paclitaxel and docetaxel are integral to our treatment of breast...

A study conducted in mice has revealed that maternal milk provides an essential signal that triggers the maturation of heart metabolism after birth, allowing the neonatal heart to function correctly and ensuring postnatal survival. The study shows that the fatty acid gamma-linolenic acid (GLA), present in breast milk, binds to the retinoid X receptor (RXR) protein found in heart cells. RXR acts as a nutritional sensor of lipids and vitamin A derivatives, altering gene expression and influencing biological functions such as immunity, cell differentiation, and metabolism. Once activated by maternal GLA, RXR initiates genetic programs that equip mitochondria, the energy...

A new international study has, for the first time, identified that beta-blockers could significantly enhance the therapeutic effect of anthracycline chemotherapy in triple negative breast cancer (TNBC) by reducing metastasis. Anthracyclines are a class of drugs used in chemotherapy to treat many cancers, including TNBC. Researchers have previously shown in a clinical trial that beta-blockers (most commonly used to manage blood pressure) are linked with less cancer spread. However, until now, it was unclear how beta-blockers would interact with common cancer treatments. The team used mouse models of cancer and analyzed large-scale patient clinical data, in collaboration with the Cancer...

Women with triple-negative breast cancer who received multiple antibiotic prescriptions within three years after their cancer diagnosis were more likely to experience disease recurrence and to die from their cancer than those who took fewer courses of the drugs, according to a study. The effect on survival was not due to differences in cancer severity, the study showed. The risk increased substantially with the total number and types of antibiotics prescribed for each patient. "Each additional antibiotic increased the risk of death between 5% and 18% relative to patients who weren't prescribed antibiotics," said Julia Ransohoff, MD. The researchers found...

In a study of over a million women, digital breast tomosynthesis (DBT) showed improved breast cancer screening outcomes over screening with standard digital mammography alone. Breast cancer is the most common cancer among women in the United States. Regular screening is the most reliable method for the early detection of breast cancer. Screening with two-dimensional (2-D) digital mammography alone is still the standard of care at many sites, but it has its limitations due to its inability to detect some cancers. There is a growing amount of evidence that DBT, a more advanced technology, has a higher breast cancer detection...

Scientists have discovered why breast cancer cells that have spread to the lungs may "wake up" following years of sleep, forming incurable secondary tumors. Their research reveals the mechanism that triggers this breast cancer "time bomb"—and suggests a strategy to defuse it. Patients with estrogen receptor positive (ER+) breast cancer—the most common type—have a continued risk of their cancer recurring in another part of their body for many years or even decades after their original diagnosis and treatment. When breast cancer cells spread from the first cancer in the breast to other parts of the body it is called secondary...

...Prostate Cancer Illustration Researchers have found that a single enzyme called PI5P4Kα can be targeted to kill prostate cancer. The discovery is the first of its kind and could help tackle treatment resistance in prostate cancer. Additionally, it could lead to better treatment options for other types of cancer, including those affecting the breast, skin, and pancreas. By inhibiting one enzyme, scientists from Sanford Burnham Prebys can kill prostate cancer cells when other treatments can’t. For the first time, researchers have discovered that prostate cancer can be killed by targeting a single enzyme, called PI5P4Kα. The findings, published recently in...

NANTUCKET — For anyone who enjoys the free ebb and flow of ocean air and currents over their bare skin, the coast is now clear for people of all genders to legally go topless on Nantucket beaches. Seven months after Nantucket voters approved a bylaw amendment specifically to allow all people — including women — freely to eschew torso coverings while spending time on the island's beaches, Attorney General Maura Healey has given the change her seal of approval. Her endorsement was required before the so-called "Gender Equity on Beaches" amendment could become Nantucket law. Nantucket is the first town...

Patients with early-stage breast cancer who had a pathologic complete response (pCR) to neoadjuvant chemotherapy may be able to skip surgery and receive standard radiation treatment with a low chance of disease recurrence, according to a study. The trial evaluated the likelihood of breast cancer returning in patients who are in complete remission after receiving chemotherapy and radiation without surgery. Each of the 31 patients followed had a complete response to chemotherapy and none had a breast tumor recurrence after a median follow-up of 26.4 months. High responses are indicated by state-of-the-art breast imaging-guided, vacuum-assisted core biopsy (VACB). These results...

Date Issued: September 8, 2022 The U.S. Food and Drug Administration (FDA) is informing the public about reports of cancers, including squamous cell carcinoma (SCC) and various lymphomas, in the scar tissue (capsule) that forms around breast implants. The various lymphomas reported are not the same as the lymphomas described in previous FDA Communications as Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL). The FDA learned about these reports through our continual postmarket review of breast implants and our ongoing collaboration with external stakeholders. After preliminary review of published literature as part of our ongoing monitoring of the safety of breast...

A study showed a significant overall survival benefit with ribociclib plus endocrine therapy for postmenopausal patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. The randomized Phase III MONALEESA-2 trial is the first demonstration of a survival advantage with a front-line CDK4/6 inhibitor in postmenopausal patients with HR+/HER2- advanced breast cancer. The results showed a median survival of 63.9 months with front-line ribociclib, a CDK4/6 inhibitor, and the aromatase inhibitor letrozole, compared to 51.4 months with hormone therapy alone. The estimated six-year survival rate was 44.2% with ribociclib, compared with 32% for placebo. Previously...

Woman with breast cancer had metastatic lesions in chest wall (top, left) and liver (bottom, left). After receiving the immunotherapy, tumors shrank completely. Recent scans (R) show she is cancer free more than 5 years later. Credit: The National Cancer Institute (NCI) ========================================================================================== An experimental form of immunotherapy that uses an individual’s own tumor-fighting immune cells could potentially be used to treat people with metastatic breast cancer, according to results from an ongoing clinical trial led by researchers at the National Cancer Institute’s (NCI) Center for Cancer Research, part of the National Institutes of Health. Many people with metastatic breast...

A woman who had fallen asleep on a United Airlines flight from Las Vegas to Virginia was stunned when she awoke to a man touching her breast, federal officials said. According to court documents, the woman had drifted off on a Christmas Eve flight from Las Vegas McCarran International Airport to Washington Dulles International Airport when she woke up to Ivan Lopez leaning over her “repeatedly rubbing her right breast,” officials said in a statement Wednesday.

Not being mean, just asking…. Is Bill Gates transitioning? https://twitter.com/REMASCULATE/status/1396902353870082048

Joe Biden traveled to Erie, Pennsylvania on Saturday promising to create a million new good paying jobs that he’s never created in 47 years in office. Biden was breathing heavily after he took off his mask. He also wiped his nose and mouth. Science! Then Creepy Uncle Joe said this… “You’re trying your breast, but it never feels like enough.” WATCH:

A groundbreaking study has found a breast cancer treatment that takes just 10 days could be just as effective as a more invasive version that lasts around six weeks. A decade-long analysis of accelerated partial breast cancer radiation - which involves targeting only the affected area - on patients with early-stage cases appeared to have the same impact as one that targets the full breast and can take between four and seven weeks, the researchers said. “APBI is a safe and less invasive treatment as compared to whole breast irradiation,” said the University of Florence’s Dr. Icro Meattini, who presented...